Oppenheimer analyst Esther Rajavelu downgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Outperform to Perform with a price target of $29.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE